Research graph
References from Mycophenolate and azathioprine in fibrotic interstitial lung disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
10.1056/nejmoa1113354 · 2012 · External reference
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
10.1056/nejmoa1402582 · 2014 · External reference
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
10.1056/nejmoa1402584 · 2014 · External reference
Nerandomilast in patients with idiopathic pulmonary fibrosis
10.1056/nejmoa2414108 · 2025 · External reference
Nerandomilast in patients with progressive pulmonary fibrosis
10.1056/nejmoa2503643 · 2025 · External reference
Nintedanib in progressive fibrosing interstitial lung diseases
10.1056/nejmoa1908681 · 2019 · External reference
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease
10.1183/13993003.02533-2024 · 2026 · External reference
Causal inference about the effects of interventions from observational studies in medical journals
10.1001/jama.2024.7741 · 2024 · External reference
Target trial emulation: a framework for causal inference from observational data
10.1001/jama.2022.21383 · 2022 · External reference
How to estimate the effect of treatment duration on survival outcomes using observational data
10.1136/bmj.k182 · 2018 · External reference
The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation
10.1007/s40471-024-00346-2 · 2024 · External reference
Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement
10.1183/13993003.00158-2025 · 2025 · External reference
Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline
10.1164/rccm.202005-2032st · 2020 · External reference
A structural approach to selection bias
10.1097/01.ede.0000135174.63482.43 · 2004 · External reference
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
10.1002/sim.6607 · 2015 · External reference
Emulating a trial of joint dynamic strategies: an application to monitoring and treatment of HIV-positive individuals
10.1002/sim.8120 · 2019 · External reference
Per-protocol analyses of pragmatic trials
10.1056/nejmsm1605385 · 2017 · External reference
Sensitivity analysis in observational research: introducing the e-value
10.7326/m16-2607 · 2017 · External reference
10.1007/978-1-4757-3294-8
10.1007/978-1-4757-3294-8 · 2000 · External reference
The R package geepack for generalized estimating equations
10.18637/jss.v015.i02 · 2006 · External reference
Predicting survival across chronic interstitial lung disease: the ILD-GAP model
10.1378/chest.13-1474 · 2014 · External reference
A multidimensional index and staging system for idiopathic pulmonary fibrosis
10.7326/0003-4819-156-10-201205150-00004 · 2012 · External reference
Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis
10.1016/j.chest.2016.10.029 · 2016 · External reference
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
10.1183/23120541.00016-2017 · 2017 · External reference
Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study
10.2147/tcrm.s173154 · 2018 · External reference
Characteristics and risk factors of interstitial pneumonia with autoimmune features
10.1016/j.rmed.2023.107500 · 2024 · External reference
Unclassifiable interstitial lung diseases: clinical characteristics and survival
10.1111/resp.12931 · 2017 · External reference
Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory
10.1016/j.chest.2022.11.035 · 2022 · External reference
Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease
10.1016/j.rmed.2016.11.007 · 2016 · External reference
The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example
10.1158/1055-9965.epi-22-0495 · 2022 · External reference
Methodologies for the emulation of biomarker-guided trials using observational data: a systematic review
10.3390/jpm15050195 · 2025 · External reference
De-mystifying the clone-censor-weight method for causal research using observational data: a primer for cancer researchers
10.1002/cam4.70461 · 2024 · External reference
Cyclophosphamide versus placebo in scleroderma lung disease
10.1056/nejmoa055120 · 2006 · External reference
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
10.1016/s2213-2600(22)00359-9 · 2022 · External reference
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial
10.1183/13993003.02071-2022 · 2023 · External reference
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases
10.1002/acr.25348 · 2024 · External reference
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
10.1016/s2213-2600(16)30152-7 · 2016 · External reference
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology
10.1164/rccm.201203-0513ci · 2012 · External reference
Roles of T lymphocytes in pulmonary fibrosis
10.1189/jlb.0707504 · 2008 · External reference
Clinical and functional characteristics of patients with unclassifiable interstitial lung disease (uILD): long-term follow-up data from European IPF Registry (eurIPFreg)
10.3390/jcm9082499 · 2020 · External reference
Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory
10.1016/j.chest.2018.08.1076 · 2019 · External reference
Associations of interstitial lung disease subtype and CT pattern with lung function and survival
10.1136/thorax-2024-222149 · 2025 · External reference
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
10.1183/13993003.00441-2023 · 2023 · External reference
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis
10.1183/13993003.02872-2020 · 2021 · External reference
Molecular endotypes predict differential response to immunosuppressant therapy in non-idiopathic pulmonary fibrosis interstitial lung disease
10.1093/ajrccm/aamag006 · 2026 · External reference
Competing causes of death in idiopathic pulmonary fibrosis
10.1164/rccm.202403-0595rl · 2024 · External reference
